Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 32M P/E - EPS this Y 25.00% Ern Qtrly Grth -
Income -28.96M Forward P/E -1.47 EPS next Y - 50D Avg Chg 17.00%
Sales 202k PEG -0.04 EPS past 5Y - 200D Avg Chg 31.00%
Dividend N/A Price/Book 0.93 EPS next 5Y 25.00% 52W High Chg -21.00%
Recommedations 2.00 Quick Ratio 1.65 Shares Outstanding 50.75M 52W Low Chg 128.00%
Insider Own 8.82% ROA -66.64% Shares Float 45.42M Beta -0.15
Inst Own 8.09% ROE -118.94% Shares Shorted/Prior 477.18K/427.05K Price 0.66
Gross Margin 79.21% Profit Margin - Avg. Volume 125,429 Target Price -
Oper. Margin -21,544.62% Earnings Date May 13 Volume 105,092 Change 3.12%
About AIM ImmunoTech Inc.

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

AIM ImmunoTech Inc. News
04/29/24 AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
04/25/24 AIM ImmunoTech Announces Release of the Next CEO Corner Segment
04/15/24 AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
04/10/24 AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
04/02/24 AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
03/28/24 AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
03/26/24 AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
03/25/24 AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
03/15/24 AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
03/07/24 AIM ImmunoTech Announces Launch of CEO Corner Platform
02/29/24 AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
02/14/24 AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
02/08/24 AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
01/24/24 AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
01/22/24 AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer
01/10/24 AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
01/05/24 AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting
04:05 PM Kellner Seeking Expedited Appeal of Delaware Court Finding that Nomination Notice was Properly Denied
12/29/23 Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board’s Determination that Activist Group’s Nominations Are Invalid
11/28/23 AIM ImmunoTech Provides Update Regarding Annual Meeting
AIM Chatroom

User Image jalal81 Posted - 7 minutes ago

$AIM

User Image Pitbull28 Posted - 2 hours ago

$AIM crazy to see we’re still at this price level. I’ve been holding long and strong with a lot of the OGs here💪

User Image Zman08765 Posted - 3 hours ago

$AIM there is a lot of speculation going on with this loan, the players involved, and the strategy behind it. I don’t buy into any of it. It’s a super risky scenario, and they needed the money, and desperate people do desperate things. If they weren’t this far along with decent trial data, I’d just go ahead and write this off as a loss. However, as far along as they are with good trail data, I’m just going to hold what I have. I’m not bullish or bearish. Just gonna HOLD. The curiosity I have coupled with my gut reaction to bail, is worth it at this point. So I guess if I had to sum up my position. This is red or green on a roulette wheel and kind of fun! Alright Tommy boy, from one veteran to another. This is either “Semper Fi”, or “Semper Fi F$&@ the other guy”. Your call.✌️

User Image Teleboy Posted - 3 hours ago

$AIM Friday update: *SEC 424B5 Prospectus issued on Wednesday. I would encourage investors to read it for themselves (Link below) See also threads by @micklemas and @Petrology *10K and CEO presentations very positive (esp. the ovarian cancer updates) *Excellent interim data from the combo $AZN Pancreatic trial and the combo $MRK UPitt recurrent Ovarian; other positive updates from TNBC, Melanoma, and this week's Dutch trial Pancreatic dosing safety data Waiting to hear: 1. Detailed UPitt ovarian cancer data update due Q2 NCT03734692 (phase 1 and 2) 2. Takeover/licensing negotiations progress. 3. TNBC final trial results with Keytruda and Celebrex $PFE NCT03599453 (phase 1) https://www.sec.gov/Archives/edgar/data/946644/000149315224017432/form424b5.htm

User Image momo2021 Posted - 5 hours ago

$AIM why doesn't bully post anyone about his TOM obsession and the naked shorts who already know 1800-dilution

User Image Jasonbush Posted - 11 hours ago

$AIM let’s freaking go, the drug absolutely works the day of reckoning is coming.

User Image cobra97 Posted - 18 hours ago

$AIM

User Image skepticalbee Posted - 21 hours ago

$AIM I think we just need to think of AIM like Baby Yoda. It was founded in 1990. At age only 34, it's still in its infancy and has barely had any time to accomplish anything yet. This is what happens when your parent (Tom) is himself as old as dirt. In that sense, I'm neither bullish nor bearish. I'm Yodish.

User Image Everydayisasaturday Posted - 1 day ago

$AIM

User Image micklemas Posted - 1 day ago

$AIM this post in a convo below is worth resharing, in case folks missed it (I suspect many of us have blocked the original poster of the convo). Appreciate the insight @Petrology, sounds reasonable.

User Image Teleboy Posted - 1 day ago

$AIM Another takeover in the targeted radiology cancer space: Novartis buys Mariana Oncology. $1bn up front with further potential milestone payments. It looks like it is very early in the development phase. https://www.biospace.com/article/novartis-buys-mariana-oncology-in-1b-acquisition-bolsters-radiopharma-assets/

User Image PercyFinn Posted - 1 day ago

$AIM Equels is getting up to $15M from Atlas Sciences, LLC for 9.975M shares roughly ~$1.50/share as per S-1 filed with the Securities and Exchange Commission on April 19, 2024 More cash on hand

User Image Teleboy Posted - 1 day ago

$AIM Found this interesting. Looking at the short volume of total shares sold each day shows the following for the last 30 days: AIM 52.66% (the number is 60.67% since April 15) TSLA 49.60% Ford 44.76% Apple 39.44% Nvidia 43.44% Given that we know from the news that shorts have been going after Tesla, what does it say about the price of AIM's stock given the much higher proportion of shares being shorted on a daily basis? If Tesla struggles to deal with them? https://chartexchange.com/symbol/nyseamerican-aim/short-volume/

User Image Manipulation13F Posted - 1 day ago

$AIM

User Image skepticalbee Posted - 1 day ago

$AIM I'm asking the following genuinely, seeking informed responses: Let's just pretend for argument sake AIM lines up a buyer. Equels and the Board own so little of the company. What incentive is there for them to sell it for a large buyout, rather than negotiating other sweetheart deals for themselves? I'm sure this is regulated to a large extent. But I also wouldn't be surprised if there are self-dealing avenues they can go down.

User Image ultimatebastos Posted - 1 day ago

$AIM I think we should dare to think about why they suddenly need to create new stock repressentibg 23% of the company? Isn't tha a little weird?

User Image Jobisblessed Posted - 1 day ago

$AIM The preferential shares that I read about, CUSIP 00901B204, can anyone provide any history with regard to them? When did they come about? Have these been outstanding for a long time? Do they have any relationship to the most recent potential offering up to 50 million shares?

User Image rayk1 Posted - 1 day ago

$AIM so will Equals announce the multibillion $ buyout in the next few weeks, before they run out of money or will he dilute first the hell out of the stock to pocket even more money for Hidalgo's well being????

User Image lktrader Posted - 2 days ago

$AIM Good day to buy. Adding here ⬆️

User Image Mikep9959 Posted - 2 days ago

$AIM there is someone buying at 40 trolling the hedgies

User Image Teleboy Posted - 2 days ago

$AIM A review article discussing the role of TLRs and their potential for treatments. Table 2 is interesting as it lists many combo trials with drugs like Keytruda (pembrolizumab) and Ampligen (rintatolimod). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11057423/

User Image Jasonbush Posted - 04/30/24

$AIM how badly has the FDA failed sick patients

User Image thisismyself Posted - 04/30/24

$AIM A few days after my eye surgery, a strange phenomenon occurred. I saw dozens of small, bright, star like dots, simultaneously. Ranging all the way from the top of my left eye to the top of my right eye. I could barely see them when my eyes were open, but they were quite clear and bright when my eyes were closed. Shining like little stars, like sparkles. Imagine if you looked at someone's eyes, and you saw a really long line of shining stars all along the top of their eyes. Here's the kicker: the lights were seen above BOTH eyes. Even the eye that had no surgery done! When I went for follow-up after the eye surgery, I told the doctor about what I encountered. She said she has no explanation for how that could occur. Look at the gif, look at the snow when it is in sparkle form. Then imagine dozens of those all along my eyes. That's what I saw. And it lasted for about 2 days.

User Image DontInvestLikeMe Posted - 04/30/24

$AIM This is the reality of things, folks. I fear it won't get better from here.

User Image momo2021 Posted - 04/30/24

$AIM bully who is woke and calls other people bully's for getting destroyed on this junk stock 🤣

User Image momo2021 Posted - 04/30/24

$AIM bully boy on ST since december 2013 and 6508 ideas how is it possible to never post a winner ever no winners ever jai wei if not true we will all wait for your proof of a winner go 🤡 more dilution otw

User Image Teleboy Posted - 04/30/24

$AIM @ultimatebastos Has me blocked but i noticed him saying preferential shares had been deleted. Where did he see that? Link would be great. Thanks.

User Image ultimatebastos Posted - 04/30/24

$AIM I don't know what they are doing but they deleted the preferential shares. I'm not happy with that.

User Image cobra97 Posted - 04/29/24

$AIM Another Bio buyout…. Some day we will be awarded! https://www.businesswire.com/news/home/20240429316382/en/Deciphera-Pharmaceuticals-to-be-Acquired-by-ONO-Pharmaceutical-For-2.4-Billion

User Image StockStories2 Posted - 04/29/24

$AIM yawn $4 yrs waiting going on to $7 wtf

Analyst Ratings
Maxim Group Buy Oct 10, 19
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Equels Thomas K CEO & President CEO & President Nov 27 Buy 0.443 33,861 15,000 640,697 11/27/23
Equels Thomas K CEO & President CEO & President Sep 29 Buy 0.441 22,676 10,000 606,836 09/29/23
Equels Thomas K CEO & President CEO & President Aug 25 Buy 0.669 8,222 5,501 584,160 08/25/23
Equels Thomas K CEO & President CEO & President Aug 24 Buy 0.667 14,993 10,000 575,938 08/24/23
Equels Thomas K CEO & President CEO & President Jul 17 Buy 0.59 16,950 10,000 560,945 07/17/23
APPELROUTH STEWART Director Director Jan 03 Buy 0.31 80,646 25,000 217,063 01/04/23
Rodino Peter W III COO, Secretary, Gen... COO, Secretary, Gen. Counsel Jan 03 Buy 0.31 80,646 25,000 143,839 01/04/23
Equels Thomas K CEO & President CEO & President Jan 03 Buy 0.31 161,291 50,000 543,995 01/04/23